Publications by authors named "Andre Scheen"

Claim this Profile
[
[Holistic and personalized management of type 2 diabetes].
André Scheen, Nicolas Paquot

Rev Med Liege· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[New paradigm in the management of type 2 diabetes].
André Scheen

Rev Med Liege· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?
André J Scheen

Lancet Diabetes Endocrinol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Indications of direct oral anticoagulant rivaroxaban in cardiovascular disease].
André Scheen, Patrizio Lancellotti

Rev Med Liege· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Semaglutide 2.4 mg (Wegovy®) for the management of clinical obesity with weight-related complications].
André Scheen, Nathalie Esser, Jenny De Flines, Nicolas Paquot

Rev Med Liege· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations.
André J Scheen

Diabetes Metab· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies.
André J Scheen

Diabetes Metab· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Plea for an early diagnosis of people at risk of developing symptomatic type 1 diabetes].
André Scheen, Madeleine Wera, Jean-Christophe Philips, Julie Fudvoye, Marie-Christine Lebrethon

Rev Med Liege· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Biomarkers for an early detection of patients at risk of renal or cardiovascular disease].
André Scheen, Pierre Delanaye, François Jouret, Patrizio Lancellotti, Étienne Cavalier

Rev Med Liege· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Tirzepatide (Mounjaro®) : a GIP/GLP-1 receptor dual agonist for the treatment of type 2 diabetes].
André Scheen

Rev Med Liege· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucagon-like peptide-1 receptor agonists and alcohol use disorders: An emerging unexpected beneficial effect.
André J Scheen

Diabetes Obes Metab· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obesity and global warming: A two-way relationship?
André Scheen

Ann Endocrinol (Paris)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[From clinical practice guidelines to personalized medicine : two guides to be implemented in health care].
André Scheen

Rev Med Liege· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Gap between guidelines and clinical practice : from epidemiological evidence to solutions to remove barriers].
André Scheen

Rev Med Liege· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Guidelines for the basic management of chronic kidney disease].
Pierre Delanaye, Nicolas Paquot, François Jouret, André Scheen

Rev Med Liege· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Updated European guidelines for the management of hypercholesterolaemia].
Caroline Wallemacq, André Scheen

Rev Med Liege· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[SURMOUNT-OSA study : tirzepatide improves obstructive sleep apnoea in patients with obesity].
André Scheen

Rev Med Liege· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weight loss therapy and addiction: Increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists.
André J Scheen

Diabetes Metab· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[How to manage type 2 diabetes in the elderly].
Emmanuel Beck, André Scheen

Rev Med Liege· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies.
André J Scheen

Diabetes Metab· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Éditorial. Laissons-nous aller à rêver d'un monde meilleur !].
André Scheen

Rev Med Liege· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Patient with type 2 diabetes and progressive chronic kidney disease].
André Scheen, Pierre Delanaye

Rev Med Liege· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Tirzepatide : overview of clinical studies SURPASS in type 2 diabetes and SURMOUNT in obesity].
André Scheen

Rev Med Liege· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Finerenone and cardiorenal protection : from controlled clinical trials to real-life clinical practice].
Jean-Christophe Philips, Régis Radermecker, André Scheen

Rev Med Liege· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[New outcome studies with injectable semaglutide in different at risk populations].
André Scheen, Pierre Delanaye, Patrizio Lancellotti

Rev Med Liege· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis